# Sermorelin Research: The GHRH(1-29) Evidence, Study by Study > Sermorelin research, read straight: the GHRH-receptor mechanism, the pediatric and aging GH/IGF-1 trials, the pharmacokinetics, and the reported and theoretical concerns — each finding cited to source. Mechanism, the human GH/IGF-1 trials, pharmacokinetics, the analog comparisons, and the honest concerns — each panel one finding, each figure cited. ## The short version Sermorelin research is unusually quotable, so this page reads it as a board of figures. Sermorelin is the working front-end of GHRH (the brain's "make growth hormone" signal). In GH-deficient children it roughly doubled first-year growth speed [1]. In older men it pushed growth hormone and IGF-1 (the liver's growth signal) back toward young-adult levels [2]. It works fast and clears fast — minutes in the blood, but about three hours of raised growth hormone per dose [3]. Below, each finding gets its own panel, with the study and the numbers attached. None of it is dosing guidance. ## Sermorelin mechanism of action The sermorelin mechanism of action begins at one receptor. As the active 1-29 fragment of GHRH, it binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on the anterior pituitary's somatotrophs [11]. Binding activates the Gs / adenylate-cyclase / cAMP / protein kinase A cascade, raising intracellular cAMP and switching on PKA. Downstream, that drives GH gene transcription, pulsatile GH release, and a trophic (growth-promoting) effect on the somatotrophs themselves [11]. The released GH then raises hepatic IGF-1, and IGF-1 plus somatostatin feed back to restrain further GH release [11]. Because sermorelin acts upstream and leaves those brakes intact, it reinforces the natural pulsatile pattern rather than overriding it — the physiologic argument an editorial made for secretagogues over recombinant GH in adult GH insufficiency [4]. The full neuroregulation of GH secretion, including the GHRH, somatostatin, and ghrelin inputs, is detailed in a comprehensive Endocrine Reviews synthesis [11]. ## Does sermorelin work? The human GH/IGF-1 trials The clearest efficacy evidence is in two populations. In a multicenter trial of prepubertal GH-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth: first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [1]. In healthy older men (mean 68), 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high dose, those values no longer differed from young men, with no effect on fasting glucose [2]. Those are the established results. What remains open is long-term adult efficacy: an Annals of Internal Medicine editorial judged the use of GH secretagogues to prevent or treat the effects of aging "not yet ready for prime time" [5]. ## Sermorelin half-life: short by design The sermorelin half-life is one of its best-characterized properties. In 30 healthy men, intravenous GHRH(1-29)NH2 elicited GH release at doses as low as 0.25 mcg/kg, peaking at 1-2 mcg/kg; the plasma half-life sits around 10-12 minutes, yet a single dose elevated serum GH for about 3 hours [3]. Intranasal bioavailability was only 3-5% [3]. That clearance is the engineering problem the next generation of analogs solved — see [sermorelin vs CJC-1295](/vs-cjc-1295) for the DAC and PEGylation half-life-extension chemistry [10]. ## What studies report over time Reframed from anecdotal "sermorelin before and after" reports, the measured trajectory is this. Biochemically, GHRH(1-29) raises GH within minutes and holds it elevated for about 3 hours [3]. Measurable IGF-1 and body-composition changes developed over weeks to months in the studied populations — dose-related 24-hour GH and IGF-1 increases after 14 days in older men [2], and in the GHRH-analog cognition trial, a 117% IGF-1 rise and a 7.4% reduction in body fat over 20 weeks [6]. In GH-deficient children, first-year height velocity rose from ~4.1 to 7-8 cm/year [1]. These are trial outcomes over defined study periods, not a treatment timeline anyone should expect. ## Sermorelin vs Ipamorelin: GHRH analog vs GHRP Sermorelin vs ipamorelin is a comparison of two different mechanisms, not two versions of one. Sermorelin is a GHRH-receptor analog — it acts on the GHRH receptor on somatotrophs [11]. Ipamorelin is a growth-hormone-releasing peptide (GHRP): it acts on the ghrelin / GH-secretagogue receptor, a separate receptor system [11]. Both raise GH, but through distinct upstream signals, which is why the two classes are studied — and sometimes discussed together — as complementary rather than interchangeable. The neuroregulation review lays out how the GHRH, somatostatin, and ghrelin inputs converge on GH secretion [11]. This site documents the GHRH side of that picture. ## Sermorelin among GHRH analogs (tesamorelin) Within the GHRH-analog family, sermorelin vs tesamorelin marks the line between the native fragment and a stabilized derivative. Tesamorelin is a stabilized synthetic GHRH analog (approved for HIV-associated lipodystrophy) used in much of the body-composition and cognition literature cited here as drug-class evidence — including the controlled cognition trial that raised IGF-1 117% and lowered body fat 7.4% over 20 weeks [6]. Sermorelin is the unmodified GHRH(1-29); tesamorelin is engineered for stability. The 2025 Nature Reviews Endocrinology review situates both within the broader account of GHRH agonists and antagonists in health and disease [12]. ## Sermorelin and sleep GHRH has a genuine physiologic role in promoting slow-wave sleep, and slow-wave sleep is when most nocturnal GH is released [11] — the rationale behind bedtime dosing in the studies. That sleep-promoting effect is also blunted with age. The neuroregulation literature treats GHRH's sleep-endocrine effects as time-of-day dependent [11]. Individual sleep experiences vary and are not equivalent to the controlled sleep-EEG findings. ## Why bedtime dosing is studied The body's largest natural GH pulse occurs during early slow-wave sleep, so studies typically dosed GHRH(1-29) at bedtime to reinforce that nocturnal pulse [11]. The sleep-endocrine effects of GHRH depend on the timing of administration [11]. This explains the study rationale; it is not a personal dosing instruction. ## Sermorelin and fat loss GHRH-axis stimulation can change body composition in studies: the related GHRH analog tesamorelin reduced visceral fat versus placebo in its trial program, and the 20-week cognition trial recorded body fat dropping 7.4% [6]. Pulsatile GH also participates in regulating fasting lipolysis [11]. Evidence for sermorelin *specifically* as a fat-loss agent in healthy adults is limited, and body-composition marketing outruns the data. ## Is sermorelin effective for weight loss? The body-composition literature centers on the stabilized analog tesamorelin reducing visceral adipose tissue [6], not on sermorelin as a weight-loss drug. Anti-aging and body-composition marketing outpaces the actual evidence for GHRH(1-29) in healthy adults, and an Annals editorial cautioned against treating GH secretagogues as proven aging interventions [5]. ## Sermorelin and muscle The muscle evidence is indirect. GHRH-axis stimulation raises GH and IGF-1 [2], and reviews discuss GH/IGF-1 modulation as a candidate strategy against age-related muscle loss (sarcopenia) [12]. No controlled trial shows sermorelin itself builds muscle in healthy adults; the muscle-building claims outrun the data. ## Sermorelin and IGF-1 Sermorelin raises IGF-1 in the studied populations. GHRH(1-29) raised IGF-1 dose-dependently in older men, with high-dose values no longer differing from young men [2], and GH-secretagogue treatment raised serum IGF-1 in older subjects [6]. Because IGF-1 rises through the body's own feedback-regulated GH release, the increase stayed within a physiologic range in these trials [6][11]. ## Reported and theoretical concerns On sermorelin side effects, the trial record is reassuring but not blank. The most common findings in trials were mild, transient injection-site reactions and reversible anti-GHRH antibodies that did not interfere with growth [1]. Long-term GHRH-analog dosing in older subjects sometimes showed mild glucose-tolerance changes or transient hyperlipidemia. Two cautions are theoretical but real. Because GH and IGF-1 are mitogenic — they drive cell growth — chronically raising them carries a theoretical oncologic caution for any GH-axis intervention, even one that works through feedback-regulated pulsatile secretion [11]. And GH secretagogues, including GHRH analogs, are prohibited in sport by WADA under hormone and metabolic modulators (S2), with dedicated detection methods in place. --- Script Sermorelin lays the GHRH(1-29) record out as a bento board of cited panels — the receptor mechanism, the pediatric and aging GH/IGF-1 figures, the cognition signal, and the honest gaps — a reference console for the literature, never a clinic, a pharmacy, or a prescription.